Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors

Acta Oncologica

Volumn 52, Issue 4, 2013, Pages 736-744

  Bentzen, Anne Gry ^a,b   Balteskard, Lise ^a,c   Wanderås, Eva Hoff ^d   Frykholm, Gunilla ^e,f   Wilsgaard, Tom ^b   Dahl, Olav ^g,h   Guren, Marianne Gronlie ^d  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORTHERN NORWAY REGIONAL HEALTH AUTHORITY   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f NORWEGIAN RADIATION PROTECTION AUTHORITY   (Norway)

^g UNIVERSITY OF BERGEN   (Norway)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANUS CANCER; ANXIETY; ARTICLE; BLOATING; CANCER STAGING; CANCER SURVIVOR; CHEMORADIOTHERAPY; CONSTIPATION; CROSS-SECTIONAL STUDY; DIARRHEA; DYSPAREUNIA; DYSPNEA; DYSURIA; FATIGUE; FECES INCONTINENCE; FEMALE; FLATULENCE; FOLLOW UP; HUMAN; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NOCTURIA; PAIN; POLLAKISURIA; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL FUNCTION; SOCIAL INTERACTION; TINNITUS; URINARY FREQUENCY; URINE INCONTINENCE; CONTROLLED STUDY; NEUROTOXICITY; QUESTIONNAIRE; SEXUAL DYSFUNCTION; SOCIAL STATUS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANUS NEOPLASMS; CASE-CONTROL STUDIES; CHEMORADIOTHERAPY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NORWAY; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; SURVIVORS; TIME FACTORS;

EID: 84875922338     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.770599     Document Type: Article

References (31)

1. Glynne-Jones R, Northover JM, CervanteSa, g roup EGW. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v87-92.
2. Ajani J A, W inter K A, G underson L L, P edersen J, Benson AB, 3rd, Thomas CR, Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fl uorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008; 299: 1914-21.
3. Bentzen AG, G uren MG, W anderas EH, Frykholm G, Tveit KM, Wilsgaard T, et al. Chemoradiotherapy of anal carcinoma: Survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys 2012; 83: e173-80.
4. Vistad I, C vancarova M, F ossa SD, K ristensen GB. Postradiotherapy morbidity in long-term survivorSafter locally advanced cervical cancer: How well do physicians'assessmentSagree with those of their patients? Int J Radiat Oncol Biol Phys 2008; 71: 1335-42.
5. AllaLaS, S prangers M A, Laurencet F, Reymond M A, Kurtz JM. Assessment oFlong-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999; 80: 1588-94.
6. Jephcott C R, Paltiel C, H ay J. Q uality of life after nonsurgical treatment of anal carcinoma: A case control study oFlong-term survivors. Clin Oncol (R Coll Radiol) 2004; 16: 530-5.
7. Welzel G, H agele V, W enz F, M ai S K. Q uality of life outcomes in patients with anal cancer after combined radiochemotherapy. Strahlenther Onkol 2011; 187: 175-82.
8. Provencher S, O ehler C, Lavertu S, J olicoeur M, F ortin B, Donath D. Quality of life and tumor controLafter shorTsplitcourse chemoradiation for anal canal carcinoma. Radiat Oncol 2010; 5: 41.
9. Das P, Cantor SB, Parker CL, Z ampieri JB, B aschnageLa, Eng C, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 2010; 116: 822-9.
10. Aaronson NK, A hmedzai S, B ergman B, B ullinger M, CulLa, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
11. Whistance R N, C onroy T, C hie W, C ostantini A, S ezer O, Koller M, et al. ClinicaLand psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 2009; 45: 3017-26.
12. Fayers P, A aronson NK, B jordal K, G roenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 scoring manual, 3rDed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
13. Osoba D, R odrigues G, M yles J, Z ee B, Pater J. I nterpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-44.
14. Cavaletti G, Frigeni B, Lanzani F, M attavelli L, S usani E, Alberti P, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools. Eur J Cancer 2010; 46: 479-94.
15. Oldenburg J, F ossa S D, D ahLaA. Scale for chemotherapyinduced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 2006; 15: 791-800.
16. Hjermstad MJ, F ayers PM, B jordal K, K aasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: The QLQ-C30 (-3). J Clin Oncol 1998; 16: 1188-96.
17. van de Poll-Franse LV, M ols F, G undy CM, C reutzberg CL, Nout RA, Verdonck-de Leeuw IM, et al. Normative data for the EORTC QLQ-C30 anDeORTC-sexuality items in the general Dutch population. Eur J Cancer 2011; 47: 667-75.
18. Burkett VS, C leeland CS. S ymptom burden in cancer survivorship. J Cancer Surviv 2007; 1: 167-75.
19. Norton N J. The perspective of the patient. G astroenterology 2004; 126: S175-9.
20. Andreyev HJ, W otherspoon A, Denham JW, H auer-Jensen M.'Pelvic radiation disease': New understanding and new solutions for a new disease in the era of cancer survivorship. Scand J Gastroenterol 2011; 46: 389-97.
21. Bruheim K, T veit KM, S kovlunDe, B alteskard L, Carlsen E, Fossa SD, et al. Sexual function in femaleSafter radiotherapy for rectal cancer. Acta Oncol 2010; 49: 826-32.
22. Bruheim K, Guren MG, D ahLaA, S kovlunDe, B alteskard L, Carlsen E, et al. Sexual function in maleSafter radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 1012-7.
23. Lind H, W aldenstrom AC, D unberger G, a l-Abany M, Alevronta E, Johansson KA, et al. Late symptoms in long term gynaecological cancer survivorSafter radiation therapy: A population-based cohorTstudy. Br J Cancer 2011; 105: 737-45.
24. Bruheim K, G uren MG, S kovlunDe, H jermstad MJ, Dahl O, Frykholm G, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 1005-11.
25. Fransson P, L und JA, D amber JE, K lepp O, W iklund F, Fossa S, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009; 10: 370-80.
26. Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, et al. Quality of life anDemotional distress in early stage and locally advanced cervical cancer patients: A prospective, longitudinal study. Gynecol Oncol 2012; 124: 389-94.
27. McKenna SP. M easuring patient-reported outcomes: Moving beyond misplaced common sense to hard science. BMC Med 2011; 9: 86.
28. Sprangers M A, Schwartz C E. I ntegrating response shift into health-related quality of life research: A theoretical model. Soc Sci Med 1999; 48: 1507-15.
29. Kachnic LA, Tsai HK, C oen JJ, B laszkowsky LS, Hartshorn K, Kwak EL, et al. Dose-painted intensitymodulated radiation therapy for anal cancer: A multiinstitutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012; 82: 153-8.
30. Ng M, L eong T, C hander S, Chu J, K neebone A, Carroll S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlaSand planning guidelines for intensitymodulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys 2012; 83: 1455-62.
31. Sogaard AJ, S elmer R, B jertness E, Thelle D. The Oslo Health Study: The impact of self-selection in a large, population-based survey. Int J Equity Health 2004; 3: 3.